Platforms for Personalized Polytherapeutics Discovery in COVID-19

The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Christopher, Onweni, Chidinma, Zambito, Victoria, Fairweather, DeLisa, McCormick, Kathryn, Ebihara, Hideki, Caulfield, Thomas, Zhang, Yu Shrike, Freeman, W. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979270/
https://www.ncbi.nlm.nih.gov/pubmed/33753053
http://dx.doi.org/10.1016/j.jmb.2021.166945
_version_ 1783667246796636160
author Hopkins, Christopher
Onweni, Chidinma
Zambito, Victoria
Fairweather, DeLisa
McCormick, Kathryn
Ebihara, Hideki
Caulfield, Thomas
Zhang, Yu Shrike
Freeman, W. David
author_facet Hopkins, Christopher
Onweni, Chidinma
Zambito, Victoria
Fairweather, DeLisa
McCormick, Kathryn
Ebihara, Hideki
Caulfield, Thomas
Zhang, Yu Shrike
Freeman, W. David
author_sort Hopkins, Christopher
collection PubMed
description The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.
format Online
Article
Text
id pubmed-7979270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-79792702021-03-23 Platforms for Personalized Polytherapeutics Discovery in COVID-19 Hopkins, Christopher Onweni, Chidinma Zambito, Victoria Fairweather, DeLisa McCormick, Kathryn Ebihara, Hideki Caulfield, Thomas Zhang, Yu Shrike Freeman, W. David J Mol Biol Perspective The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems. The Author(s). Published by Elsevier Ltd. 2021-05-14 2021-03-20 /pmc/articles/PMC7979270/ /pubmed/33753053 http://dx.doi.org/10.1016/j.jmb.2021.166945 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Hopkins, Christopher
Onweni, Chidinma
Zambito, Victoria
Fairweather, DeLisa
McCormick, Kathryn
Ebihara, Hideki
Caulfield, Thomas
Zhang, Yu Shrike
Freeman, W. David
Platforms for Personalized Polytherapeutics Discovery in COVID-19
title Platforms for Personalized Polytherapeutics Discovery in COVID-19
title_full Platforms for Personalized Polytherapeutics Discovery in COVID-19
title_fullStr Platforms for Personalized Polytherapeutics Discovery in COVID-19
title_full_unstemmed Platforms for Personalized Polytherapeutics Discovery in COVID-19
title_short Platforms for Personalized Polytherapeutics Discovery in COVID-19
title_sort platforms for personalized polytherapeutics discovery in covid-19
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979270/
https://www.ncbi.nlm.nih.gov/pubmed/33753053
http://dx.doi.org/10.1016/j.jmb.2021.166945
work_keys_str_mv AT hopkinschristopher platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT onwenichidinma platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT zambitovictoria platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT fairweatherdelisa platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT mccormickkathryn platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT ebiharahideki platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT caulfieldthomas platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT zhangyushrike platformsforpersonalizedpolytherapeuticsdiscoveryincovid19
AT freemanwdavid platformsforpersonalizedpolytherapeuticsdiscoveryincovid19

Ejemplares similares